Bayer's Second Annual Virtual Walk for Hemophilia Raises Funds, Generates
Excitement in the Hemophilia Community
The National Hemophilia Foundation Annual Meeting
WAYNE, N.J., Nov. 8, 2012
WAYNE, N.J., Nov. 8, 2012 /PRNewswire/ --At the National Hemophilia
Foundation (NHF) Annual Meeting in Orlando today, Bayer HealthCare, the NHF
and Save One Life celebrated the successful conclusion of the second annual
Virtual Walk for Hemophilia, an engaging, online contest designed to raise
awareness and funds for those living with bleeding disorders.
With an innovative spin on the fundraising walk idea, The Virtual Walk for
Hemophilia (www.walkforhemophilia.com) employs a website where people
interested in supporting those with hemophilia can virtually "walk" online.
Virtual walkers choose which NHF chapter they support, and create a customized
avatar to represent themselves in the virtual walk. At the time the Virtual
Walk ended on November 6th, more than 32,000 people – those with and without
hemophilia – had signed up. To put this number in perspective, the total
number of people with hemophilia in the U.S. is currently estimated to be
Bayer provided $30,000 in sponsorship funds to the national office of the NHF
and an additional $33,500 in sponsorship funds to the five chapters with the
greatest number of walkers, for a total of more than $60,000. Virtual walkers
also had a chance to double the points they contributed to their chapter, by
participating in an actual, physical fundraising walk. This way, Bayer was
able to provide a Virtual Walk, while also supporting chapters' own efforts at
hosting fundraising walks throughout the country.
"Bayer's Virtual Walk was an exciting initiative for us this year," said Cindy
Komar, Executive Director, Arizona Hemophilia Foundation. "Encouraging people
to sign up for the Walk was a great way for us to engage with our
constituents, and it reenergized our whole team. We're grateful for the
sponsorship funds Bayer provided to us, and know that they will help us do
even more for the hemophilia community in the coming year."
The chapters receiving sponsorship funds are:
First place: Arizona Hemophilia Association, with 9,004 walkers, received
Second place: Bleeding Disorders Alliance Illinois, with 8,714 walkers,
Third place: Texas Central Hemophilia Association, with 6,833 walkers,
Fourth place: Nevada Chapter, National Hemophilia Foundation, with 3,625
walkers received $2,500
Fifth place: Nebraska Chapter, National Hemophilia Foundation, with 2,083
walkers, received $1,000
In addition to the sponsorship funds going to the NHF and its chapters, Bayer
provided $7,000 in sponsorship funds to Save One Life, a non-profit,
international organization that offers people and organizations the
opportunity to sponsor a child or adult with a bleeding disorder in a
developing country. In total, Bayer provided more than $70,000 in sponsorship
funds to organizations in the hemophilia community.
According to Leslie Donato, Vice President/General Manager, Hematology, Bayer
HealthCare, "In just its second year, The Virtual Walk for Hemophilia has
become a fun and important way for the hemophilia community to come
together.We're gratified to see a strong response again this year, and are
especially pleased to be able to provide this support to Save One Life and to
the NHF and its participating chapters."
About Hemophilia A
Hemophilia A, also known as factor VIII deficiency or classical hemophilia is
largely an inherited bleeding disorder in which one of the proteins needed to
form blood clots in the body is missing or reduced. Hemophilia A is the most
common type of hemophilia and is characterized by prolonged or spontaneous
bleeding, especially into the, joints, muscles or internal organs.
Approximately 400,000 people around the world have hemophilia.
About Bayer HealthCare Pharmaceuticals Inc.
Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals
business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare
is one of the world's leading, innovative companies in the healthcare and
medical products industry, and combines the activities of the Animal Health,
Consumer Care, Medical Care, and Pharmaceuticals divisions. As a specialty
pharmaceutical company, Bayer HealthCare provides products for General
Medicine, Hematology, Neurology, Oncology and Women's Healthcare. The
company's aim is to discover and manufacture products that will improve human
health worldwide by diagnosing, preventing and treating diseases.
BAYER® and the Bayer Cross® are registered trademarks of Bayer.
This news release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management. Various
known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. These
factors include those discussed in Bayer's public reports which are available
on the Bayer website at www.bayer.com. The company assumes no liability
whatsoever to update these forward-looking statements or to conform them to
future events or developments.
Intended for U.S. media only
SOURCE Bayer HealthCare Pharmaceuticals Inc.
Contact: Media, Jane Ward, +1-973-420-2876, firstname.lastname@example.org
Press spacebar to pause and continue. Press esc to stop.